Regeneron Pharmaceuticals, Inc… (NASDAQ:REGN)

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis (RA) is an autoimmune disease that attacks tissues within the joints, and it is accompanied by chronic swelling and pain. This systemic disease can affect the whole body, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alcoa, Cemex, Comerica, Facebook, GM, Incyte, Proofpoint, Regeneron and More

Stocks were hammered on Friday for the end of a volatile week, but stock indices were indicated higher on Monday, with a 150-point rise in the Dow Jones industrial average ...
Read Full Story »

10 Large Cap Stocks the Top Hedge Funds Are Buying Now

While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by simply mimicking what legendary investors like Warren Buffett hold. With ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Capital One, Domino’s, Home Depot, Mosaic, Regenron, Six Flags, US Steel, Walmart and More

Stocks have returned to a period of volatility, but Tuesday's selling pressure has been mostly mitigated as futures stabilized on Wednesday's early trading hours. The trend that has worked without ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City, Regeneron, Visa and More

Stocks have hit all-time highs too many times to easily count in 2017. The bull market is now nearing nine years old, and 2017 only has two trading session remaining ...
Read Full Story »

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

With the U.S. House and the Senate now working together to patch up differences between the two tax reform bills, one thing looks pretty certain: In one shape or another, ...
Read Full Story »

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

With 2017 coming to an end, investors are wondering how they should be investing for 2018 and beyond. At the start of December, the Dow was up just over 20% ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal, Stratasys and More

Stocks have hit new highs this week and went over 23,000 for the first time. Even after a weak opening on Thursday, the market managed to come back, and shares ...
Read Full Story »

4 Red-Hot Merrill Lynch US 1 Momentum Stocks to Buy for the Rest of 2017

Despite the market hitting all-time highs yet again this week, and with the seasonably difficult time of the year for stocks rolling around, many of the top analysts and strategists ...
Read Full Story »

Merrill Lynch Top Health Care Stock Picks for September: Focus on Large Cap Biotech

Merrill Lynch recently released its September RIC Report, noting key strategy views and showing many sector views. One such view from the firm was that health care stocks are currently ...
Read Full Story »

10 Top Stocks Analysts Want You to Sell Now

After weeks of new highs after new highs in the Dow and S&P 500, investors have finally started to see some selling of stocks in August. This has historically not ...
Read Full Story »

Top Analyst Upgrades & Downgrades: Boeing, Chipotle, First Solar, Goldman Sachs, IBM, Lockheed Martin, Lululemon, Vertex and Many More

Stocks were indicated to open only slightly higher on Wednesday after a mixed bag of corporate earnings. What investors need to understand is that the major equity indexes remain just ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Carbonite, Coach, Credit Suisse, DaVita, Intuit, Pandora, ONEOK, Regeneron and More

Stocks may have listed sideways for much of last week, but major indexes were indicated to open higher on Monday. The bull market is now well over eight years old, ...
Read Full Story »

Tuesday’s Biggest Winners and Losers in the S&P 500

June 20, 2017: The S&P 500 closed lower, down 0.66% at 2,437.16. The DJIA closed lower 0.3% at 21,467.45. Separately, the Nasdaq closed down 0.8% at 6,188.03. Although Monday was ...
Read Full Story »

15 Companies Bracing for Big ASCO Reactions

This year marks the 53rd Annual Meeting for the American Society of Clinical Oncology (ASCO), where biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (June ...
Read Full Story »